Article
Predictors of the response to gefitinib in refractory non-small cell lung cancer.
Clinical cancer research : an official journal of the American Association for Cancer Research - 15 Mar 2005
Kim Kyu-Sik, Jeong Ju-Yeon, Kim Young-Chul, Na Kook-Joo, Kim Yun-Hyeon, Ahn Sung-Ja, Baek Sun-Mi, Park Chang-Soo, Park Chang-Min, Kim Yu-Il, Lim Sung-Chul, Park Kyung-Ok
Abstract excerpt
Gefitinib, an epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, has a response rate of 10% to 20% in refractory non-small cell lung carcinoma. Although female gender, adenocarcinoma, and never having smoked are possible markers of a favorable response, mutations of the EGFR gene...
Topics
- Adenocarcinoma
- Adenocarcinoma, Bronchiolo-Alveolar
- Adult
- Aged
- Aged, 80 and over
- Antineoplastic Agents
- Carcinoma, Non-Small-Cell Lung
- Carcinoma, Squamous Cell
- Disease Progression
- ErbB Receptors
- Feasibility Studies
- Female
- Gefitinib